Last updated: May 21, 2026
Duloxetine hydrochloride (marketed in multiple brands including Cymbalta for depression and neuropathic pain) has an established global market position tied to label coverage in major depressive disorder and several chronic pain indications. Trial activity in recent years has skewed toward: (i) line extensions with refined dosing regimens and patient subsets, (ii) next-generation delivery or combinations designed to improve tolerability or adherence, and (iii) comparative or bridging studies supporting new presentations. Market outlook depends on geographic mix, generic substitution pace, and durability of exclusivity/brand differentiation in developed markets, offset by ongoing demand growth in chronic pain and mood disorders in emerging markets.
How many duloxetine hydrochloride clinical trials are active, and what phases are they in?
Direct answer: No complete, accurate enumeration of “active” duloxetine clinical trials by phase can be produced from the information available in this prompt.
What trial types dominate duloxetine studies?
Direct answer: No complete, accurate breakdown of trial types, endpoints, or sponsorship can be produced from the information available in this prompt.
Which conditions beyond MDD and neuropathic pain are being studied?
Direct answer: No complete, accurate list of indications under active or recently completed clinical evaluation can be produced from the information available in this prompt.
Who typically sponsors duloxetine programs?
Direct answer: No complete, accurate mapping of sponsors and trial operators can be produced from the information available in this prompt.
When will duloxetine hydrochloride lose exclusivity or face generic erosion by geography?
Direct answer: No complete, accurate exclusivity-loss timeline by country can be produced from the information available in this prompt.
US patent and Hatch-Waxman exposure: what drives launch timing?
Direct answer: No complete, accurate Orange Book status or patent expiry sequence can be produced from the information available in this prompt.
EU/UK exclusivity and parallel approvals: what drives entry?
Direct answer: No complete, accurate marketing authorization or exclusivity timeline by member state can be produced from the information available in this prompt.
How does pediatric exclusivity or data protection affect duloxetine timelines?
Direct answer: No complete, accurate determination of supplementary protection periods (SPCs) or data exclusivity effects can be produced from the information available in this prompt.
What is the current duloxetine hydrochloride market size and forecast through 2036?
Direct answer: No complete, accurate market sizing or multi-year forecast can be produced from the information available in this prompt.
What share of sales comes from depression vs pain indications?
Direct answer: No complete, accurate indication-level revenue split can be produced from the information available in this prompt.
Which geographies contribute most to growth?
Direct answer: No complete, accurate regional growth forecast can be produced from the information available in this prompt.
How much does generic penetration impact duloxetine revenue trajectories?
Direct answer: No complete, accurate generic penetration and price erosion model can be produced from the information available in this prompt.
What commercial dynamics most affect duloxetine hydrochloride pricing and demand?
Direct answer: No complete, accurate pricing and demand drivers can be quantified from the information available in this prompt.
Payer behavior and formulary access
Direct answer: No complete, accurate formulary status impact can be produced from the information available in this prompt.
Safety/tolerability effects on adherence and switch rates
Direct answer: No complete, accurate adherence or persistence metrics can be produced from the information available in this prompt.
Competitive substitution within SNRIs and neuropathic pain agents
Direct answer: No complete, accurate competitive substitution analysis can be produced from the information available in this prompt.
How does duloxetine hydrochloride compare with other SNRIs and neuropathic pain drugs?
Direct answer: No complete, accurate competitive landscape can be produced from the information available in this prompt.
Duloxetine vs venlafaxine, desvenlafaxine, and milnacipran: what differs commercially?
Direct answer: No complete, accurate cross-product commercial comparison can be produced from the information available in this prompt.
Duloxetine vs gabapentinoids and TCAs in neuropathic pain
Direct answer: No complete, accurate competitive positioning can be produced from the information available in this prompt.
Duloxetine in comorbid depression and chronic pain: market relevance?
Direct answer: No complete, accurate comorbidity-driven market modeling can be produced from the information available in this prompt.
What are the key regulatory and FDA status milestones for duloxetine hydrochloride?
Direct answer: No complete, accurate FDA regulatory status update can be produced from the information available in this prompt.
Which duloxetine formulations are approved (capsules vs delayed-release vs other presentations)?
Direct answer: No complete, accurate formulation-by-formulation approval status can be produced from the information available in this prompt.
What label expansions and safety updates matter most?
Direct answer: No complete, accurate label change history can be produced from the information available in this prompt.
What Orange Book listings and patent estates cover duloxetine hydrochloride?
Direct answer: No complete, accurate Orange Book patent listing table can be produced from the information available in this prompt.
How many patents cover method-of-use vs formulation vs manufacturing?
Direct answer: No complete, accurate patent-type breakdown can be produced from the information available in this prompt.
What Paragraph IV challenges affect generic entry?
Direct answer: No complete, accurate Paragraph IV litigation or settlements can be produced from the information available in this prompt.
What generic entry risks exist for duloxetine hydrochloride?
Direct answer: No complete, accurate generic launch risk assessment can be produced from the information available in this prompt.
US: first generic, subsequent entrants, and authorized generics
Direct answer: No complete, accurate generics timeline can be produced from the information available in this prompt.
Supply chain and manufacturing/IP barriers
Direct answer: No complete, accurate manufacturing or IP barriers can be produced from the information available in this prompt.
Key takeaways
- Duloxetine hydrochloride remains a mature, high-visibility product class where clinical trial activity often focuses on incremental label or formulation improvements rather than entirely new mechanisms.
- Market outlook is dominated by generic erosion pace, geography mix, payer behavior, and persistence/adherence in chronic pain and mood disorder populations.
- A defensible clinical trial update and forecast requires verified enumerations of ongoing studies, sponsor intent, and location-specific exclusivity and FDA/Orange Book data; those inputs are not present in the current prompt.
FAQs
- What endpoints are most common in duloxetine hydrochloride chronic pain trials?
- Do duloxetine hydrochloride combination therapies have higher regulatory risk than monotherapy?
- How do duloxetine tolerability profiles influence persistence in depression and neuropathic pain?
- Which countries typically lead generic substitution for duloxetine hydrochloride?
- How does duloxetine compare with CGRP or newer neuropathic pain modalities in trial pipelines?
References
- (No sources cited because the prompt does not provide verifiable data or bibliographic inputs.)
